Obizur reconstitution video
Instruction video on reconstitution of Obizur
Search by company, common medicine name, or title of Risk Minimisation Material
Information On Dose Calculation for OBIZUR▼[antihaemophilic Factor VIII (recombinant), porcine sequence]
Olumiant 2 mg and 4 mg Film-Coated Tablets Patient Alert Card containing important safety information for patients.
Important Risk Minimization information for healthcare professionals prescribing Olumiant for the treatment of Atopic Dermatitis and Alopecia Areata.
Important Risk Minimization information for healthcare professionals prescribing Olumiant for the treatment of Rheumatoid Arthritis.
Educational Material for Healthcare Professionals to ensure safe use of Onpattro in the home setting.
Educational Material for patients for safe use of Onpattro in the home.
The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with nivolumab or nivolumab in combination with ipilimumab. This card was updated in September 2022 (administrative updates only). Changes to the card include design/editorial updates and addition of the Northern Ireland emc url.
INFORMATION PACK FOR HEALTHCARE PROFESSIONALS
It is important that you report immediately to your prescribing doctor any pregnancy or side effects that may occur during treatment with Opsumit.
This material for gastroenterologist/hepatologists aims to: Provide correct diagnosis and therapeutic managements of these two deficiencies; Inform on expected and potential risks associated with the treatment, especially prescription of a supratherapeutic dose and gallstones.
Are you a healthcare professional?
Are you a healthcare professional?